Novo Nordisk is aware of the current HRT shortages being experienced by some pharmaceutical companies, and how distressing this must be for those women affected.
Novo Nordisk stocks are not affected by these current supply issues and, as always, our priority is ensuring that people receive the care and treatment that they need.
As such, we are working closely with the Government to continue to increase our UK supply and ensure our HRT products are available for all of those in need, including women who were previously prescribed alternatives. We want to reassure women in the UK that we are confident that we can supply the current demand.
If you have any concerns, please contact your GP, or visit https://www.womens-health-concern.org/.
This page is intended for members of the UK public:
UK20NNG00001 February 2020